These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 35518522)

  • 1. COVID-19-Associated Pulmonary Aspergillosis in a Patient Treated With Remdesivir, Dexamethasone, and Baricitinib: A Case Report.
    Shimada A; Ohnaka S; Kubo K; Nakashima M; Nagai A
    Cureus; 2022 Apr; 14(4):e23755. PubMed ID: 35518522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19-associated pulmonary aspergillosis in a Japanese man: A case report.
    Imoto W; Himura H; Matsuo K; Kawata S; Kiritoshi A; Deguchi R; Miyashita M; Kaga S; Noda T; Yamamoto K; Yamada K; Uchida K; Nishimura T; Yamamoto H; Mizobata Y; Kakeya H
    J Infect Chemother; 2021 Jun; 27(6):911-914. PubMed ID: 33674201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autopsy Findings of Severe COVID-19 Pneumonia Combined with Pulmonary Aspergillosis, Pneumothorax, and Pulmonary Thromboembolisms.
    Kanaji N; Kimura N; Kondo A; Watanabe N; Inoue T; Mizoguchi H; Komori Y; Kawada K; Kadowaki N
    Am J Case Rep; 2023 May; 24():e939251. PubMed ID: 37221822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of the combination of baricitinib, remdesivir, and dexamethasone in hypoxic adults with COVID-19: A retrospective study.
    Yasuda Y; Hirayama Y; Uemasu K; Arasawa S; Iwashima D; Takahashi KI
    Respir Med Res; 2022 May; 81():100903. PubMed ID: 35316675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A fatal case report of invasive pulmonary aspergillosis and mucormycosis coinfection in an immunocompetent patient with coronavirus disease 2019 in Korea.
    Kim JH; Kim M; Lim S; Park SY; Jegal Y; Lee T; Kang BJ
    Acute Crit Care; 2023 Aug; 38(3):382-388. PubMed ID: 35791656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Baricitinib in Combination With Remdesivir and Steroid in COVID-19 Treatment: A Multicenter Retrospective Study.
    So JM; Umeh C; Noriega S; Stratton E; Aseri M; Gupta RC
    Cureus; 2021 Dec; 13(12):e20620. PubMed ID: 35106192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Retrospective Study of Dexamethasone, Remdesivir, and Baricitinib in Severe COVID-19.
    Ngo DQ; Hamid K; Rana H; Cardinale M; Frenia D; Ghani N; Redel H
    Can J Infect Dis Med Microbiol; 2022; 2022():9209618. PubMed ID: 35845297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tocilizumab and Baricitinib for Recovery From Acute Exacerbation of Combined Pulmonary Fibrosis and Emphysema Secondary to COVID-19 Infection: A Case Report.
    Kai Y; Matsuda M; Suzuki K; Kasamatsu T; Kajita A; Uno K; Muro S
    Cureus; 2022 Mar; 14(3):e23411. PubMed ID: 35481309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk Factors for Coronavirus Disease 2019 (COVID-19)-Associated Pulmonary Aspergillosis in Critically Ill Patients: A Nationwide, Multicenter, Retrospective Cohort Study.
    Kim SH; Hong JY; Bae S; Lee H; Wi YM; Ko JH; Kim B; Joo EJ; Seok H; Shi HJ; Yoo JR; Hyun M; Kim HA; Jang S; Mun SJ; Kim J; Kim MC; Jung DS; Kim SH; Peck KR
    J Korean Med Sci; 2022 May; 37(18):e134. PubMed ID: 35535369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19-Associated Pulmonary Aspergillosis Complicated by Severe Coronavirus Disease: Is Detection of Aspergillus in Airway Specimens Before Disease Onset an Indicator of Antifungal Prophylaxis?
    Kitayama T; Tone K; Makimura K; Takagi M; Kuwano K
    Cureus; 2023 Mar; 15(3):e36212. PubMed ID: 37069870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy with predicted body weight-based dexamethasone, remdesivir, and baricitinib in patients with COVID-19 pneumonia: A single-center retrospective cohort study during 5th wave in Japan.
    Hirasawa Y; Terada J; Shionoya Y; Fujikawa A; Isaka Y; Takeshita Y; Kinouchi T; Koshikawa K; Tajima H; Kinoshita T; Tada Y; Tatsumi K; Tsushima K
    Respir Investig; 2023 Jul; 61(4):438-444. PubMed ID: 37119744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stenotrophomonas maltophilia Infection Associated with COVID-19: A Case Series and Literature Review.
    Ishikawa K; Nakamura T; Kawai F; Uehara Y; Mori N
    Am J Case Rep; 2022 Jul; 23():e936889. PubMed ID: 35852985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment of proven coronavirus disease 2019-associated pulmonary aspergillosis with liposomal amphotericin B in a patient with bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation.
    Nakaya Y; Nakashima Y; Harada N; Yamada K; Makuuchi Y; Kuno M; Takakuwa T; Okamura H; Nanno S; Nishimoto M; Koh H; Nakagama Y; Kido Y; Kanno T; Suzuki T; Nakamae H; Kakeya H; Hino M
    J Infect Chemother; 2023 Feb; 29(2):223-227. PubMed ID: 36379403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.
    Marconi VC; Ramanan AV; de Bono S; Kartman CE; Krishnan V; Liao R; Piruzeli MLB; Goldman JD; Alatorre-Alexander J; de Cassia Pellegrini R; Estrada V; Som M; Cardoso A; Chakladar S; Crowe B; Reis P; Zhang X; Adams DH; Ely EW;
    Lancet Respir Med; 2021 Dec; 9(12):1407-1418. PubMed ID: 34480861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic Pulmonary Aspergillosis During Convalescence From Severe COVID-19 Treated With Oral Itraconazole: A Report of Two Cases.
    Horiuchi H; Utada S; Shinomiya Y; Miyagawa T; Sogo A; Niida S; Okano H; Suzuki N; Otsuka T; Miyazaki H; Furuya R
    Cureus; 2022 Jul; 14(7):e27281. PubMed ID: 36039212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical impact of combination therapy with baricitinib, remdesivir, and dexamethasone in patients with severe COVID-19.
    Izumo T; Kuse N; Awano N; Tone M; Sakamoto K; Takada K; Muto Y; Fujimoto K; Saiki A; Ito Y; Matsumoto H; Inomata M
    Respir Investig; 2021 Nov; 59(6):799-803. PubMed ID: 34413006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19-Associated Pulmonary Aspergillosis (CAPA).
    Dimopoulos G; Almyroudi MP; Myrianthefs P; Rello J
    J Intensive Med; 2021 Oct; 1(2):71-80. PubMed ID: 36785564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Covid-19 associated pulmonary aspergillosis with extensive cavitary pneumonia: A case report.
    Hanif S; Iqbal M; Sethi SM
    J Pak Med Assoc; 2023 Jan; 73(1):174-176. PubMed ID: 36842034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis.
    Verweij PE; Brüggemann RJM; Azoulay E; Bassetti M; Blot S; Buil JB; Calandra T; Chiller T; Clancy CJ; Cornely OA; Depuydt P; Koehler P; Lagrou K; de Lange D; Lass-Flörl C; Lewis RE; Lortholary O; Liu PL; Maertens J; Nguyen MH; Patterson TF; Rijnders BJA; Rodriguez A; Rogers TR; Schouten JA; Wauters J; van de Veerdonk FL; Martin-Loeches I
    Intensive Care Med; 2021 Aug; 47(8):819-834. PubMed ID: 34160631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.